US20020071827A1 - Bone graft substitute composition - Google Patents
Bone graft substitute composition Download PDFInfo
- Publication number
- US20020071827A1 US20020071827A1 US09/915,997 US91599701A US2002071827A1 US 20020071827 A1 US20020071827 A1 US 20020071827A1 US 91599701 A US91599701 A US 91599701A US 2002071827 A1 US2002071827 A1 US 2002071827A1
- Authority
- US
- United States
- Prior art keywords
- parts
- weight
- composition
- calcium sulfate
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 156
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 90
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims abstract description 97
- 238000002156 mixing Methods 0.000 claims abstract description 45
- 239000000126 substance Substances 0.000 claims abstract description 37
- 210000002805 bone matrix Anatomy 0.000 claims abstract description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 32
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 30
- 239000008223 sterile water Substances 0.000 claims description 27
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 26
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 22
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 22
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 claims description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 125000002091 cationic group Chemical group 0.000 claims description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 9
- 229920000609 methyl cellulose Polymers 0.000 claims description 9
- 239000001923 methylcellulose Substances 0.000 claims description 9
- 235000010981 methylcellulose Nutrition 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 7
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- 235000011152 sodium sulphate Nutrition 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 5
- 239000005695 Ammonium acetate Substances 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- 235000019257 ammonium acetate Nutrition 0.000 claims description 5
- 229940043376 ammonium acetate Drugs 0.000 claims description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 5
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 5
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 5
- 239000002953 phosphate buffered saline Substances 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- ZHZFKLKREFECML-UHFFFAOYSA-L calcium;sulfate;hydrate Chemical compound O.[Ca+2].[O-]S([O-])(=O)=O ZHZFKLKREFECML-UHFFFAOYSA-L 0.000 claims 1
- 239000000463 material Substances 0.000 description 45
- -1 vinyl alcohols Chemical class 0.000 description 17
- 238000009472 formulation Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000007547 defect Effects 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 241000282465 Canis Species 0.000 description 7
- 230000003628 erosive effect Effects 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229910052925 anhydrite Inorganic materials 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 5
- 230000002138 osteoinductive effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 230000002262 irrigation Effects 0.000 description 4
- 238000003973 irrigation Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000011507 gypsum plaster Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229920003087 methylethyl cellulose Polymers 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- JUQPZRLQQYSMEQ-UHFFFAOYSA-N CI Basic red 9 Chemical compound [Cl-].C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=[NH2+])C=C1 JUQPZRLQQYSMEQ-UHFFFAOYSA-N 0.000 description 1
- QMGYPNKICQJHLN-UHFFFAOYSA-M Carboxymethylcellulose cellulose carboxymethyl ether Chemical compound [Na+].CC([O-])=O.OCC(O)C(O)C(O)C(O)C=O QMGYPNKICQJHLN-UHFFFAOYSA-M 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000012227 artificial bone substitute Substances 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 229940052223 basic fuchsin Drugs 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000004068 calcium phosphate ceramic Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000031902 chemoattractant activity Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000004820 osteoconduction Effects 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
- A61L27/365—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/446—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2835—Bone graft implants for filling a bony defect or an endoprosthesis cavity, e.g. by synthetic material or biological material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the invention relates to bone graft substitute compositions.
- Gitelis U.S. Pat. No. 5,147,403, issued Sep. 15, 1992, discloses a method or technique for implanting a prosthesis comprising the steps of first preparing the surface of a bone to receive the prosthesis, then applying a calcium sulfate suspension in free flowing form to the prepared bone surface, and then seating the prosthesis to the coated bone surface.
- Sottosanti U.S. Pat. No. 5,366,507, discloses a composition for use in bone tissue regeneration, the composition containing a barrier material and a graft material.
- the barrier material can be calcium sulfate
- the graft material may consist of a composite graft material containing demineralized, freeze-dried, allogeneic bone and calcium sulfate.
- Sottosanti U.S. Pat. No. 5,569,308, discloses a method for use in bone tissue regeneration including first filling a graft site with graft material, and then placing a layer of barrier material over at least a portion of the graft material.
- the barrier material can be calcium sulfate, while the graft material may consist a composite graft material containing demineralized, freeze-dried, allogeneic bone and calcium sulfate.
- Osteotech, Inc. markets a bone graft substitute under the mark Grafton®. It is comprised of demineralized bone matrix and glycerol as a carrier material.
- the carrier material, glycerol is a viscous, gel-like, weak alcohol that is hydrophilic and water-soluble. It is recognized by the Food and Drug Administration as a “Generally Regarded As Safe” substance.
- DePuy, Inc. markets a bone graft substitute under the mark DynaGraft®. It is comprised of demineralized bone matrix and poloxamer as a carrier material. Poloxamer is a reverse phase polymer which becomes more viscous with increasing temperature.
- a bone graft substitute composition including calcium sulfate, a mixing solution such as sterile water, and a plasticizing substance such as carboxymethylcellulose, and having an extended set time and sufficient robustness to withstand fluid impact with minimal erosion.
- a basic concept of the present invention is to provide bone graft substitute composition having an extended set time and sufficient robustness to withstand fluid impact with minimal erosion for expanded clinical applications.
- the bone graft substitute composition of the present invention comprises, in general, calcium sulfate; a mixing solution such as sterile water; and a plasticizing substance such as carboxymethylcellulose.
- One object of the present invention is to provide a bone graft substitute composition that can be mixed into a paste and then loaded into a syringe and ejected for an extended period of time (e.g., more than ten minutes).
- Another object of the present invention is to provide a bone graft substitute composition that can be mixed into a putty and then handled and formed into desired shapes for an extended period of time (e.g., more than ten minutes).
- the bone graft substitute composition of the present invention comprises, in general, a quantity of calcium sulfate, a quantity of fluid (e.g., sterile water), and a quantity of a plasticizing substance (e.g., carboxymethylcellulose) which provides a resultant composition that is robust and has an extended set time.
- the extended set time of the resultant composition provides a useful working time of at least 5 minutes to allow sufficient time for a surgeon to properly apply the bone graft substitute composition, while the robustness of the resultant composition allows the implanted composition to withstand the typical pressure of body fluids, irrigation fluids and/or suctioning with minimal material erosion, disintegration or dissolution.
- the bone graft substitute composition of the present invention may comprise a mixture of calcium sulfate; a mixing solution selected from the group consisting of sterile water, inorganic salts, and cationic surface active agents including sodium chloride, phosphate buffered saline, potassium chloride, sodium sulfate, potassium sulfate, EDTA, ammonium sulfate, ammonium acetate, and sodium acetate, etc.; and a plasticizing substance selected from the group consisting of cellulose derivatives including sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, hydroxypropylcellulose, ethylcellulose, hydroxethylcellulose and cellulose acetate butyrate, and higher molecular weight alcohols including glycerol and vinyl alcohols, etc.
- a mixing solution selected from the group consisting of sterile water, inorganic salts, and cationic surface active agents including sodium chloride, phosphate buffered saline, potassium chlor
- the bone graft substitute composition may include demineralized bone matrix.
- One formulation of the composition may be approximately 100 parts calcium sulfate by weight, 11.1 parts carboxymethylcellulose by weight, 185.2 parts water by weight, and 69.4 parts demineralized bone matrix by weight.
- Another formulation of the composition may be approximately 100 parts calcium sulfate by weight, 6.3 parts carboxymethylcellulose by weight, and 31 parts water by weight.
- Another formulation of the composition may be approximately 100 parts calcium sulfate by weight, 1.2 parts carboxymethylcellulose by weight, and 31 parts water by weight.
- Another formulation of the composition may be approximately 80-120 parts calcium sulfate by weight, 1-40 parts carboxymethylcellulose by weight, and 21-250 parts water by weight.
- the composition may include a bioactive agent selected from the group consisting of demineralized bone matrix, growth factors, hyaluronic acid, bone morphogenic proteins, bone autograft, and bone marrow, etc.
- the composition may include sodium bicarbonate.
- the composition may include 0.1-2% sodium bicarbonate by weight for creating a porous structure in the resultant composition.
- Possible embodiments of the bone graft substitute composition of the present invention may include at least one additive selected from the group consisting of antiviral agent, antimicrobial agent, antibiotic agent, amino acid, peptide, vitamin, inorganic element, protein synthesis co-factor, hormone, endocrine tissue, synthesizer, enzyme, polymer cell scaffolding agent with parenchymal cells, angiogenic drug, demineralized bone powder, collagen lattice, antigenic agent, cytoskeletal agent, mesenchymal stem cells, bone digester, antitumor agent, cellular attractant, fibronectin, growth hormone, cellular attachment agent, immunosuppressant, nucleic acid, surface active agent, hydroxyapatite, penetration enhancer, bone allograft, and chunks, shards, and/or pellets of calcium sulfate.
- additives selected from the group consisting of antiviral agent, antimicrobial agent, antibiotic agent, amino acid, peptide, vitamin, inorganic element, protein synthesis co-factor, hormone
- An injectable bone graft substitute composition having the following preferred formulation: 100 parts by weight of medical grade calcium sulfate hemihydrate (MGCSH), 11.1 parts by weight of carboxymethylcellulose (CMC), 69.4 parts by weight 15 of demineralized bone matrix (DBM), and 162 parts by weight of sterile water.
- MMCSH medical grade calcium sulfate hemihydrate
- CMC carboxymethylcellulose
- DBM demineralized bone matrix
- the preferred method for mixing this putty bone graft substitute composition comprises the following steps: (1) dry blend the powder components (i.e., the calcium sulfate hemihydrate, carboxymethylcellulose, and demineralized bone matrix); (2) add the sterile water; and (3) mix or stir all components for approximately 30 seconds to one minute or until the desired putty-like consistency is achieved.
- the powder components i.e., the calcium sulfate hemihydrate, carboxymethylcellulose, and demineralized bone matrix
- the resultant injectable bone graft substitute composition has the following characteristic/criteria:
- Handability - the resultant composition should: (a) be a single cohesive bolus; (b) be able to be handled and manipulated with minimal to no material transfer (sticking) to latex gloved hand; (c) be able to be handled without material crumbling or falling apart; and (d) exhibit minimal cracking or “tearing” with extreme manipulation, e.g., hard squeezing;
- Ejectability - the resultant composition should: (a) be able to be easily manipulated, e.g., rolled into a long cylinder or other suitable shape, so as to be manually placed into an appropriate injection apparatus, e.g., a syringe; and (b) be able to be ejected through a 1 ⁇ 8 inch (0.3175 centimeter) diameter orifice with relatively little pressure required; and
- a putty bone graft substitute composition having the following preferred formulation: 100 parts by weight of medical grade calcium sulfate hemihydrate (MGCSH), 11.1 parts by weight of carboxymethylcellulose (CMC), and 47 parts by weight of sterile water.
- MMCSH medical grade calcium sulfate hemihydrate
- CMC carboxymethylcellulose
- the preferred method for mixing this putty bone graft substitute composition comprises the following steps: (1) dry blend the powder components (i.e., the calcium sulfate hemihydrate, and carboxymethylcellulose); (2) add the sterile water; and (3) mix or stir all components for approximately 30 seconds to one minute or until the desired putty-like consistency is achieved.
- the powder components i.e., the calcium sulfate hemihydrate, and carboxymethylcellulose
- the resultant putty bone graft substitute composition has the following characteristic/criteria:
- Handability - the resultant composition should: (a) be a single cohesive bolus; (b) be able to be handled and manipulated with minimal to no material transfer (sticking) to latex gloved hand; (c) be able to be handled without material crumbling or falling apart; and (d) exhibit minimal cracking or “tearing” with extreme manipulation, e.g., hard squeezing; and
- a paste bone graft substitute composition having the following preferred formulation: 100 parts by weight of medical grade calcium sulfate hemihydrate (MGCSH), 1.2 parts by weight of carboxymethylcellulose (CMC), and 31 parts by weight of sterile water.
- MMCSH medical grade calcium sulfate hemihydrate
- CMC carboxymethylcellulose
- the preferred method for mixing this putty bone graft substitute composition comprises the following steps: (1) dry blend the powder components (i.e., the calcium sulfate hemihydrate, and carboxymethylcellulose); (2) add the sterile water; and (3) mix or stir all components for approximately 30 seconds to one minute or until the desired putty-like consistency is achieved.
- the powder components i.e., the calcium sulfate hemihydrate, and carboxymethylcellulose
- the resultant paste bone graft substitute composition has the following characteristic/criteria:
- Ejectability - the resultant composition should be able to be ejected through a 1 ⁇ 8 inch (0.3175 centimeter)diameter orifice with relatively little pressure required.
- a bone graft substitute composition having the following preferred formulation: approximately 80-120 parts medical grade calcium sulfate hemihydrate by weight; approximately 21-250 parts sterile water by weight; and approximately 1-40 parts sodium carboxymethylcellulose by weight.
- This preferred formulation may include approximately 10-100 parts demineralized bone matrix by weight.
- the preferred method for mixing this bone graft substitute composition comprises the following steps: (1) dry blend the powder components (i.e., the calcium sulfate hemihydrate, and sodium carboxymethylcellulose, and, if included, the demineralized bone matrix); (2) add the sterile water; and (3) mix or stir all components for approximately 30 seconds to one minute or until the desired consistency is achieved.
- the powder components i.e., the calcium sulfate hemihydrate, and sodium carboxymethylcellulose, and, if included, the demineralized bone matrix
- add the sterile water and (3) mix or stir all components for approximately 30 seconds to one minute or until the desired consistency is achieved.
- the resultant bone graft substitute composition has the following characteristic/criteria:
- Handability - the resultant composition should: (a) be a single cohesive bolus; (b) be able to be handled and manipulated with minimal to no material transfer (sticking) to latex gloved hand; (c) be able to be handled without material crumbling or falling apart; and (d) exhibit minimal cracking or “tearing” with extreme manipulation, e.g., hard squeezing;
- Ejectability - the resultant composition should: (a) be able to be easily manipulated, e.g., rolled into a long cylinder or other suitable shape, so as to be manually placed into an appropriate injection apparatus, e.g., a syringe; and (b) be able to be ejected through a 1 ⁇ 8 inch (0.3175 centimeter) diameter orifice with relatively little pressure required; and
- the bone graft substitute composition includes calcium sulfate, e.g., calcium sulfate hemihydrate; a mixing solution, e.g., sterile water; and a plasticizing substance, e.g., hyaluronic acid or a cellulose derivative such as methylcellulose.
- the plasticizing substance can include, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, ethylcellulose, hydroxyethylcellulose, and/or cellulose acetate butyrate.
- the mixing solution can include, for example, sterile water, inorganic salt, and/or cationic surface active agent.
- the cationic surface active agent can include sodium chloride, phosphate buffered saline, potassium chloride, sodium sulfate, ammonium sulfate, ammonium acetate, or sodium acetate.
- the bone graft substitute composition includes a given amount of calcium sulfate, e.g., normalized to 100 parts by weight of CaSO 4 ⁇ 1 ⁇ 2H 2 O; an amount of the plasticizing substance sufficient to provide a good biological response, e.g., about 1 to about 10 parts, or about 1 to about 7 parts, or about 2 to about 6 parts, by weight; and a sufficient amount of the mixing solution to provide good handability, e.g., about 20 to about 40 parts, or about 20 to about 35 parts, by weight, such that the composition can be conveniently handled and shaped.
- specific compositions are a function of the plasticizing substance used in the composition.
- the composition can include 100 parts by weight of calcium sulfate, e.g., CaSO 4 ⁇ 1 ⁇ 2H 2 O; about 2 to about 7 parts, e.g., about 3 parts, by weight of HPC; and about 26 to about 32 parts, e.g., about 28 parts, by weight of the mixing solution, e.g., sterile water.
- calcium sulfate e.g., CaSO 4 ⁇ 1 ⁇ 2H 2 O
- HPC hydroxypropyl cellulose
- the mixing solution e.g., sterile water
- the composition can include 100 parts by weight of calcium sulfate, e.g., CaSO 4 ⁇ 1 ⁇ 2H 2 O; about 1 to about 6 parts, e.g., about 2 parts, by weight of HPMC; and about 23 to about 32 parts, e.g., about 25 parts, by weight of the mixing solution, e.g., sterile water.
- calcium sulfate e.g., CaSO 4 ⁇ 1 ⁇ 2H 2 O
- HPMC hydroxypropyl methyl cellulose
- the composition can include 100 parts by weight of calcium sulfate, e.g., CaSO 4 ⁇ 1 ⁇ 2H 2 O; about 4 to about 6 parts, e.g., about 5 parts, by weight of hyaluronic acid; and about 23 to about 40 parts, e.g., about 30 to about 35 parts, by weight of the mixing solution, e.g., sterile water.
- calcium sulfate e.g., CaSO 4 ⁇ 1 ⁇ 2H 2 O
- about 4 to about 6 parts e.g., about 5 parts
- hyaluronic acid e.g., about 23 to about 40 parts
- the mixing solution e.g., sterile water.
- the composition can include about 100 parts by weight of the calcium sulfate hemihydrate, about 25 to about 65 parts by weight of the mixing solution, e.g., water, and about 1.5 to about 8 parts by weight of methylcellulose.
- the composition can include about 100 parts by weight of the calcium sulfate, e.g., calcium sulfate hemihydrate, about 33.6 parts by weight of the mixing solution, e.g., water, and about 5.25 parts by weight of methylcellulose.
- compositions are formed according to the methods described above.
- Powder components e.g., calcium sulfate and plasticizing substance
- the mixing solution e.g., water
- the mixture is mixed or stirred for about 30-60 seconds or until a desired consistency is achieved.
- the resulting bone graft substitute composition is a paste or putty having similar handability, ejectability and/or robustness as described above.
- the substitute composition can be handled and shaped such that it can be conveniently positioned and secured into a surgical site.
- the composition can set up relatively hard, e.g., it can be used as an interoperative structural support, it can be resistant to substantial collapse, or it can withstand fluid impact without substantial erosion.
- the substitute composition has relatively low to no risk of transmitting infectious disease because, for example, it does not include biological materials such as materials from a cadaver.
- the composition is relatively inexpensive to produce.
- the resulting bone graft substitute can also be used as a carrier, for example, by mixing it with other materials such as allografts, antibiotics, and growth factors.
- This can the composition with versatility and flexibility by allowing a user to formulate a mixed composition according to a desired application.
- a bone graft substitute composition includes calcium sulfate, e.g., calcium sulfate hemihydrate, demineralized bone matrix, allograft materials, preferably, cancellous bone chips from a cadaver, a plasticizing substance, and a mixing solution.
- the plasticizing substance can include carboxymethylcellulose, e.g., sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methyl cellulose, ethylcellulose, hydroxyethylcellulose, and/or cellulose acetate butyrate.
- the mixing solution can include sterile water, inorganic salt, and/or cationic surface active agent.
- the cationic surface active agent can include sodium chloride, phosphate buffered saline, potassium chloride, sodium sulfate, ammonium sulfate, ammonium acetate, or sodium acetate.
- the composition can include about 80 to about 120 parts by weight of calcium sulfate, about 10 to about 100 parts by weight of demineralized bone matrix, about 10 to about 100 parts by weight of allograft materials, about 1 to about 40 parts by weight of a plasticizing substance, and about 21 to about 250 parts by weight of a mixing solution.
- the composition includes about 90 to about 110 parts by weight of calcium sulfate, about 10 to about 50 parts by weight of demineralized bone matrix, about 15 to about 50 parts by weight of cancellous bone, about 5 to about 20 parts by weight of a plasticizing substance, and about 80 to about 120 parts by weight of a mixing solution.
- the composition includes about 98 to about 102 parts by weight of calcium sulfate, about 13 to about 23 parts by weight of demineralized bone matrix, about 27 to about 33 parts by weight of cancellous bone, about 15 to about 20 parts by weight of a plasticizing substance, and about 95 to about 105 parts by weight of a mixing solution.
- the composition includes about 100 parts by weight of calcium sulfate, about 18 to about 19 parts by weight of demineralized bone matrix, about 27 to about 28 parts by weight of cancellous bone, about 17 to about 18 parts by weight of a plasticizing substance, and about 101 to about 102 parts by weight of a mixing solution.
- compositions are formed according to the methods described above.
- Powder components e.g., calcium sulfate hemihydrate, demineralized bone matrix, cancellous bone chips, and carboxymethylcellulose
- the mixing solution e.g., water
- the mixture is mixed or stirred for about 30-60 seconds or until a desired consistency is achieved.
- the resulting bone graft substitute composition is a paste or putty having similar handability, ejectability and/or robustness as described above.
- the cancellous bone chips can provide the composition with good structural support, and the relatively large surface area of the cancellous bone chips can provide the composition with good osteoconduction.
- the majority of tests done to date on the bone graft substitute composition of the present invention basically consist of mixing a specific formulation and then assessing and recording the mixing, handling, consistency, and injectability properties of the resultant material.
- Injectable Bone Graft Substitute Composition Formulations with various types and amounts of carboxymethylcellulose and demineralized bone matrix have been tested. Specific examples include: (1) carboxymethylcellulose percentages of 1-10% by weight; (2) types of carboxymethylcellulose have included high viscosity, medium viscosity, and low viscosity from 3 vendors (e.g., Aqualon® 7HF PH sodium carboxymethylcellulose from Hercules Incorporated, Hercules Plaza, 1313 North Market Street, Wilmington, Del.
- 3 vendors e.g., Aqualon® 7HF PH sodium carboxymethylcellulose from Hercules Incorporated, Hercules Plaza, 1313 North Market Street, Wilmington, Del.
- demineralized bone matrix percentages up to 65% by volume; (5) differently processed demineralized bone matrix, air dried and freeze dried; (6) demineralized bone matrix from two vendors (e.g., human freeze dried demineralized bone matrix from AlloSource, 8085 E. Harvard Ave., Denver, Col. 80231); and (7) animal demineralized bone matrix, including bovine and canine.
- Paste And Putty Bone Graft Substitute Composition were the first tests done and included formulations with compositions having 100 parts by weight medical grade calcium sulfate hemihydrate, and between 1-10% by weight carboxymethylcellulose, and between 31-200 parts by weight water. As was the case with the injectable bone graft substitute composition, mixing, handability, consistency, injectability, and robustness properties were assessed for the different formulations. Specific tests have included: (1) varying the carboxymethylcellulose percentages from 0.25% up to 10% by weight, (2) using inorganic salt solutions including 2% sodium chloride (NaCl) by weight, 2-4% sodium sulfate (Na 2 SO 4 ) by weight, and 2% potassium chloride (KCl)by weight.
- NaCl sodium chloride
- KCl potassium chloride
- the osteoinductive properties of the injectable bone graft substitute composition have been studied using an athymic mouse-intramuscular implantation model. This animal model is widely accepted as the “gold standard” for assessing osteoinductive characteristics of bone graft materials. In this model, a given amount of material is surgically placed into a muscular site. After an implantation period of four weeks, the osteoinductive response is assessed using various analytical methods, including radiography, biochemical analysis (alkaline phosphatase levels and calcium content), and histomorphometry.
- Samples to be analyzed for alkaline phosphatase activity were minced, sonicated, and extracted with water saturated butanol. The extracts were assayed for protein content using a Pierce BCA Protein Assay Kit (Pierce Chemical Co.) and measuring the conversion of para-nitrophenylphosphate (pNPP)to para-nitrophenol (pNP) with time. The results were expressed as mole pNP formed/min/ g tissue protein.
- Samples intended for histomorphometric analyses were prepared using standard histological procedures. The percent viable bone (new bone formation) was quantitated employing computer software (Adobe Photo Shop 3.0.4 and HNIH 1.61), in conjunction with a microscope equipped with a video camera. Data was reported as percent viable bone relative to the total cross-sectional area analyzed.
- the DBM used in these compositions was fresh frozen canine DBM (Veterinarian Transplant Services, Seattle, Wash.). Two methods were used to produce the test materials.
- the first material group consisted of a blend of DBM, calcium sulfate, and CMC powder that was irradiated sterilized, while the second group mixed canine DBM with the calcium sulfate-CMC blend at the time of surgery.
- the explanted humeri were sectioned transversely, radiographed, and processed for plastic imbedded undecalcified histology.
- the histologic sections were stained with basic fuchsin and toluidine blue and examined by light microscopy.
- Post-operative radiographs revealed all test materials to be well contained in the prepared cavities. Normal would healing occurred and there were no postoperative infections. Serial clinical radiographs showed a progressive decrease in materials density with time. No difference was evident between the right and left sides.
Abstract
A bone graft substitute composition can include essentially of calcium sulfate, a mixing solution, and a plasticizing substance. A bone graft substitute composition can include calcium sulfate, demineralized bone matrix, cancellous bone, a plasticizing substance, and a mixing solution.
Description
- This application is a continuation-in-part application of and claims priority to U.S. application Ser. No. 09/327,761, filed on Jun. 7, 1999, and entitled “Bone Graft Substitute Composition”, hereby incorporated by reference in its entirety.
- The invention relates to bone graft substitute compositions.
- Calcium sulfate has been clinically used for many years as a bone void filler with successful results. A preliminary patentability search produced the following patents which appear to be relevant to the present invention:
- Hanker et al., U.S. Pat. No. 4,619,655, issued Oct. 28, 1986, discloses an animal implant comprising a scaffold material composed of plaster of Paris and a non-bioresorbable calcium material (such as calcium phosphate ceramic particles) bound with the plaster of Paris; a method of inserting such a composition in fluid or semisolid form into the appropriate body location of an animal (e.g., about a fracture locus); and a method of inserting a preform of such composition into the appropriate location of an animal (e.g., at the locus of a fracture).
- Gitelis, U.S. Pat. No. 5,147,403, issued Sep. 15, 1992, discloses a method or technique for implanting a prosthesis comprising the steps of first preparing the surface of a bone to receive the prosthesis, then applying a calcium sulfate suspension in free flowing form to the prepared bone surface, and then seating the prosthesis to the coated bone surface.
- Randolph, U.S. Pat. Nos. 5,614,206, issued Mar. 25, 1997, and 5,807,567, issued Sep. 15, 1998, disclose processes for preparing pellets by mixing of calcium sulfate, water and other medicaments to provide controlled release of calcium sulfate and medicaments.
- Snyder, U.S. Pat. No. 5,425,769, issued Jun. 20, 1995, discloses a composition for an artificial bone substitute material consisting of collagen in a calcium sulfate matrix which can be rendered porous by a foaming agent. The composition is adaptable for osseous repair by adjusting the collagen and calcium sulfate in varying ratios to suit particular applications and including admixtures of growth factors.
- Sottosanti, U.S. Pat. No. 5,366,507, discloses a composition for use in bone tissue regeneration, the composition containing a barrier material and a graft material. The barrier material can be calcium sulfate, while the graft material may consist of a composite graft material containing demineralized, freeze-dried, allogeneic bone and calcium sulfate.
- Sottosanti, U.S. Pat. No. 5,569,308, discloses a method for use in bone tissue regeneration including first filling a graft site with graft material, and then placing a layer of barrier material over at least a portion of the graft material. The barrier material can be calcium sulfate, while the graft material may consist a composite graft material containing demineralized, freeze-dried, allogeneic bone and calcium sulfate.
- Hanker et al, “Setting of Composite Hydroxylapatite/Plaster Implants with Blood 5 for Bone Reconstruction,” Proceedings of the 44th Annual Meeting of the Electron Microscopy Society of America, Copyright 1986, discloses using blood as the only moistening agent in a plaster or plaster/HA mixture as long as accelerator salts are utilized, and suggests that the putty-like consistency of such compositions offers distinct advantages in moldability and workability.
- Osteotech, Inc., of Shrewsbury, N.J., markets a bone graft substitute under the mark Grafton®. It is comprised of demineralized bone matrix and glycerol as a carrier material. The carrier material, glycerol, is a viscous, gel-like, weak alcohol that is hydrophilic and water-soluble. It is recognized by the Food and Drug Administration as a “Generally Regarded As Safe” substance.
- DePuy, Inc., of Warsaw, Ind., markets a bone graft substitute under the mark DynaGraft®. It is comprised of demineralized bone matrix and poloxamer as a carrier material. Poloxamer is a reverse phase polymer which becomes more viscous with increasing temperature.
- Nothing in the known prior art discloses or suggests a bone graft substitute composition including calcium sulfate, a mixing solution such as sterile water, and a plasticizing substance such as carboxymethylcellulose, and having an extended set time and sufficient robustness to withstand fluid impact with minimal erosion.
- A basic concept of the present invention is to provide bone graft substitute composition having an extended set time and sufficient robustness to withstand fluid impact with minimal erosion for expanded clinical applications.
- The bone graft substitute composition of the present invention comprises, in general, calcium sulfate; a mixing solution such as sterile water; and a plasticizing substance such as carboxymethylcellulose.
- One object of the present invention is to provide a bone graft substitute composition that can be mixed into a paste and then loaded into a syringe and ejected for an extended period of time (e.g., more than ten minutes).
- Another object of the present invention is to provide a bone graft substitute composition that can be mixed into a putty and then handled and formed into desired shapes for an extended period of time (e.g., more than ten minutes).
- The bone graft substitute composition of the present invention comprises, in general, a quantity of calcium sulfate, a quantity of fluid (e.g., sterile water), and a quantity of a plasticizing substance (e.g., carboxymethylcellulose) which provides a resultant composition that is robust and has an extended set time. The extended set time of the resultant composition provides a useful working time of at least 5 minutes to allow sufficient time for a surgeon to properly apply the bone graft substitute composition, while the robustness of the resultant composition allows the implanted composition to withstand the typical pressure of body fluids, irrigation fluids and/or suctioning with minimal material erosion, disintegration or dissolution.
- The bone graft substitute composition of the present invention may comprise a mixture of calcium sulfate; a mixing solution selected from the group consisting of sterile water, inorganic salts, and cationic surface active agents including sodium chloride, phosphate buffered saline, potassium chloride, sodium sulfate, potassium sulfate, EDTA, ammonium sulfate, ammonium acetate, and sodium acetate, etc.; and a plasticizing substance selected from the group consisting of cellulose derivatives including sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, hydroxypropylcellulose, ethylcellulose, hydroxethylcellulose and cellulose acetate butyrate, and higher molecular weight alcohols including glycerol and vinyl alcohols, etc. The bone graft substitute composition may include demineralized bone matrix. One formulation of the composition may be approximately 100 parts calcium sulfate by weight, 11.1 parts carboxymethylcellulose by weight, 185.2 parts water by weight, and 69.4 parts demineralized bone matrix by weight. Another formulation of the composition may be approximately 100 parts calcium sulfate by weight, 6.3 parts carboxymethylcellulose by weight, and 31 parts water by weight. Another formulation of the composition may be approximately 100 parts calcium sulfate by weight, 1.2 parts carboxymethylcellulose by weight, and 31 parts water by weight. Another formulation of the composition may be approximately 80-120 parts calcium sulfate by weight, 1-40 parts carboxymethylcellulose by weight, and 21-250 parts water by weight. The composition may include a bioactive agent selected from the group consisting of demineralized bone matrix, growth factors, hyaluronic acid, bone morphogenic proteins, bone autograft, and bone marrow, etc. The composition may include sodium bicarbonate. For example, the composition may include 0.1-2% sodium bicarbonate by weight for creating a porous structure in the resultant composition. Possible embodiments of the bone graft substitute composition of the present invention may include at least one additive selected from the group consisting of antiviral agent, antimicrobial agent, antibiotic agent, amino acid, peptide, vitamin, inorganic element, protein synthesis co-factor, hormone, endocrine tissue, synthesizer, enzyme, polymer cell scaffolding agent with parenchymal cells, angiogenic drug, demineralized bone powder, collagen lattice, antigenic agent, cytoskeletal agent, mesenchymal stem cells, bone digester, antitumor agent, cellular attractant, fibronectin, growth hormone, cellular attachment agent, immunosuppressant, nucleic acid, surface active agent, hydroxyapatite, penetration enhancer, bone allograft, and chunks, shards, and/or pellets of calcium sulfate.
- An injectable bone graft substitute composition having the following preferred formulation: 100 parts by weight of medical grade calcium sulfate hemihydrate (MGCSH), 11.1 parts by weight of carboxymethylcellulose (CMC), 69.4 parts by weight 15 of demineralized bone matrix (DBM), and 162 parts by weight of sterile water.
- The preferred method for mixing this putty bone graft substitute composition comprises the following steps: (1) dry blend the powder components (i.e., the calcium sulfate hemihydrate, carboxymethylcellulose, and demineralized bone matrix); (2) add the sterile water; and (3) mix or stir all components for approximately 30 seconds to one minute or until the desired putty-like consistency is achieved.
- The resultant injectable bone graft substitute composition has the following characteristic/criteria:
- Handability - the resultant composition should: (a) be a single cohesive bolus; (b) be able to be handled and manipulated with minimal to no material transfer (sticking) to latex gloved hand; (c) be able to be handled without material crumbling or falling apart; and (d) exhibit minimal cracking or “tearing” with extreme manipulation, e.g., hard squeezing;
- Ejectability - the resultant composition should: (a) be able to be easily manipulated, e.g., rolled into a long cylinder or other suitable shape, so as to be manually placed into an appropriate injection apparatus, e.g., a syringe; and (b) be able to be ejected through a ⅛ inch (0.3175 centimeter) diameter orifice with relatively little pressure required; and
- Robustness - the resultant composition, after being placed or injected into or onto the desired location, should be able to withstand body fluids, reasonable irrigation fluids and/or suctioning with minimal material erosion, disintegration or dissolution.
- A putty bone graft substitute composition having the following preferred formulation: 100 parts by weight of medical grade calcium sulfate hemihydrate (MGCSH), 11.1 parts by weight of carboxymethylcellulose (CMC), and 47 parts by weight of sterile water.
- The preferred method for mixing this putty bone graft substitute composition comprises the following steps: (1) dry blend the powder components (i.e., the calcium sulfate hemihydrate, and carboxymethylcellulose); (2) add the sterile water; and (3) mix or stir all components for approximately 30 seconds to one minute or until the desired putty-like consistency is achieved.
- The resultant putty bone graft substitute composition has the following characteristic/criteria:
- Handability - the resultant composition should: (a) be a single cohesive bolus; (b) be able to be handled and manipulated with minimal to no material transfer (sticking) to latex gloved hand; (c) be able to be handled without material crumbling or falling apart; and (d) exhibit minimal cracking or “tearing” with extreme manipulation, e.g., hard squeezing; and
- Robustness - the resultant composition, after being placed or injected into or onto the desired location, should be able to withstand body fluids, reasonable irrigation fluids and/or suctioning with minimal material erosion, disintegration or dissolution.
- A paste bone graft substitute composition having the following preferred formulation: 100 parts by weight of medical grade calcium sulfate hemihydrate (MGCSH), 1.2 parts by weight of carboxymethylcellulose (CMC), and 31 parts by weight of sterile water.
- The preferred method for mixing this putty bone graft substitute composition comprises the following steps: (1) dry blend the powder components (i.e., the calcium sulfate hemihydrate, and carboxymethylcellulose); (2) add the sterile water; and (3) mix or stir all components for approximately 30 seconds to one minute or until the desired putty-like consistency is achieved.
- The resultant paste bone graft substitute composition has the following characteristic/criteria:
- Ejectability - the resultant composition should be able to be ejected through a ⅛ inch (0.3175 centimeter)diameter orifice with relatively little pressure required.
- A bone graft substitute composition having the following preferred formulation: approximately 80-120 parts medical grade calcium sulfate hemihydrate by weight; approximately 21-250 parts sterile water by weight; and approximately 1-40 parts sodium carboxymethylcellulose by weight. This preferred formulation may include approximately 10-100 parts demineralized bone matrix by weight.
- The preferred method for mixing this bone graft substitute composition comprises the following steps: (1) dry blend the powder components (i.e., the calcium sulfate hemihydrate, and sodium carboxymethylcellulose, and, if included, the demineralized bone matrix); (2) add the sterile water; and (3) mix or stir all components for approximately 30 seconds to one minute or until the desired consistency is achieved.
- The resultant bone graft substitute composition has the following characteristic/criteria:
- Handability - the resultant composition should: (a) be a single cohesive bolus; (b) be able to be handled and manipulated with minimal to no material transfer (sticking) to latex gloved hand; (c) be able to be handled without material crumbling or falling apart; and (d) exhibit minimal cracking or “tearing” with extreme manipulation, e.g., hard squeezing;
- Ejectability - the resultant composition should: (a) be able to be easily manipulated, e.g., rolled into a long cylinder or other suitable shape, so as to be manually placed into an appropriate injection apparatus, e.g., a syringe; and (b) be able to be ejected through a ⅛ inch (0.3175 centimeter) diameter orifice with relatively little pressure required; and
- Robustness - the resultant composition, after being placed or injected into or onto the desired location, should be able to withstand body fluids, reasonable irrigation fluids and/or suctioning with minimal material erosion, disintegration or dissolution.
- In some preferred embodiments, the bone graft substitute composition includes calcium sulfate, e.g., calcium sulfate hemihydrate; a mixing solution, e.g., sterile water; and a plasticizing substance, e.g., hyaluronic acid or a cellulose derivative such as methylcellulose. The plasticizing substance can include, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, ethylcellulose, hydroxyethylcellulose, and/or cellulose acetate butyrate. The mixing solution can include, for example, sterile water, inorganic salt, and/or cationic surface active agent. The cationic surface active agent can include sodium chloride, phosphate buffered saline, potassium chloride, sodium sulfate, ammonium sulfate, ammonium acetate, or sodium acetate.
- Generally, the bone graft substitute composition includes a given amount of calcium sulfate, e.g., normalized to 100 parts by weight of CaSO 4·½H2O; an amount of the plasticizing substance sufficient to provide a good biological response, e.g., about 1 to about 10 parts, or about 1 to about 7 parts, or about 2 to about 6 parts, by weight; and a sufficient amount of the mixing solution to provide good handability, e.g., about 20 to about 40 parts, or about 20 to about 35 parts, by weight, such that the composition can be conveniently handled and shaped. For a bone graft composition having CaSO4·½H2O and sterile water as the mixing solution, specific compositions are a function of the plasticizing substance used in the composition.
- In an embodiment having hydroxypropyl cellulose (HPC) as the plasticizing substance, the composition can include 100 parts by weight of calcium sulfate, e.g., CaSO 4·½H2O; about 2 to about 7 parts, e.g., about 3 parts, by weight of HPC; and about 26 to about 32 parts, e.g., about 28 parts, by weight of the mixing solution, e.g., sterile water.
- In an embodiment having hydroxypropyl methyl cellulose (HPMC) as the plasticizing substance, the composition can include 100 parts by weight of calcium sulfate, e.g., CaSO 4·½H2O; about 1 to about 6 parts, e.g., about 2 parts, by weight of HPMC; and about 23 to about 32 parts, e.g., about 25 parts, by weight of the mixing solution, e.g., sterile water.
- In an embodiment having hyaluronic acid as the plasticizing substance, the composition can include 100 parts by weight of calcium sulfate, e.g., CaSO 4·½H2O; about 4 to about 6 parts, e.g., about 5 parts, by weight of hyaluronic acid; and about 23 to about 40 parts, e.g., about 30 to about 35 parts, by weight of the mixing solution, e.g., sterile water.
- In yet another embodiment, the composition can include about 100 parts by weight of the calcium sulfate hemihydrate, about 25 to about 65 parts by weight of the mixing solution, e.g., water, and about 1.5 to about 8 parts by weight of methylcellulose. For example, the composition can include about 100 parts by weight of the calcium sulfate, e.g., calcium sulfate hemihydrate, about 33.6 parts by weight of the mixing solution, e.g., water, and about 5.25 parts by weight of methylcellulose.
- The compositions are formed according to the methods described above. Powder components (e.g., calcium sulfate and plasticizing substance) are dry blended. The mixing solution, e.g., water, is added to the powder components, and the mixture is mixed or stirred for about 30-60 seconds or until a desired consistency is achieved.
- The resulting bone graft substitute composition is a paste or putty having similar handability, ejectability and/or robustness as described above.
- The substitute composition can be handled and shaped such that it can be conveniently positioned and secured into a surgical site. The composition can set up relatively hard, e.g., it can be used as an interoperative structural support, it can be resistant to substantial collapse, or it can withstand fluid impact without substantial erosion. The substitute composition has relatively low to no risk of transmitting infectious disease because, for example, it does not include biological materials such as materials from a cadaver. The composition is relatively inexpensive to produce.
- The resulting bone graft substitute can also be used as a carrier, for example, by mixing it with other materials such as allografts, antibiotics, and growth factors. This can the composition with versatility and flexibility by allowing a user to formulate a mixed composition according to a desired application.
- Other preferred embodiments of a bone graft substitute composition includes calcium sulfate, e.g., calcium sulfate hemihydrate, demineralized bone matrix, allograft materials, preferably, cancellous bone chips from a cadaver, a plasticizing substance, and a mixing solution. The plasticizing substance can include carboxymethylcellulose, e.g., sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methyl cellulose, ethylcellulose, hydroxyethylcellulose, and/or cellulose acetate butyrate. The mixing solution can include sterile water, inorganic salt, and/or cationic surface active agent. The cationic surface active agent can include sodium chloride, phosphate buffered saline, potassium chloride, sodium sulfate, ammonium sulfate, ammonium acetate, or sodium acetate.
- Generally, the composition can include about 80 to about 120 parts by weight of calcium sulfate, about 10 to about 100 parts by weight of demineralized bone matrix, about 10 to about 100 parts by weight of allograft materials, about 1 to about 40 parts by weight of a plasticizing substance, and about 21 to about 250 parts by weight of a mixing solution. Preferably, the composition includes about 90 to about 110 parts by weight of calcium sulfate, about 10 to about 50 parts by weight of demineralized bone matrix, about 15 to about 50 parts by weight of cancellous bone, about 5 to about 20 parts by weight of a plasticizing substance, and about 80 to about 120 parts by weight of a mixing solution. More preferably, the composition includes about 98 to about 102 parts by weight of calcium sulfate, about 13 to about 23 parts by weight of demineralized bone matrix, about 27 to about 33 parts by weight of cancellous bone, about 15 to about 20 parts by weight of a plasticizing substance, and about 95 to about 105 parts by weight of a mixing solution. Most preferably, the composition includes about 100 parts by weight of calcium sulfate, about 18 to about 19 parts by weight of demineralized bone matrix, about 27 to about 28 parts by weight of cancellous bone, about 17 to about 18 parts by weight of a plasticizing substance, and about 101 to about 102 parts by weight of a mixing solution.
- The compositions are formed according to the methods described above. Powder components (e.g., calcium sulfate hemihydrate, demineralized bone matrix, cancellous bone chips, and carboxymethylcellulose) are dry blended. The mixing solution, e.g., water, is added to the powder components, and the mixture is mixed or stirred for about 30-60 seconds or until a desired consistency is achieved.
- The resulting bone graft substitute composition is a paste or putty having similar handability, ejectability and/or robustness as described above. The cancellous bone chips can provide the composition with good structural support, and the relatively large surface area of the cancellous bone chips can provide the composition with good osteoconduction.
- The majority of tests done to date on the bone graft substitute composition of the present invention basically consist of mixing a specific formulation and then assessing and recording the mixing, handling, consistency, and injectability properties of the resultant material.
- Injectable Bone Graft Substitute Composition: Formulations with various types and amounts of carboxymethylcellulose and demineralized bone matrix have been tested. Specific examples include: (1) carboxymethylcellulose percentages of 1-10% by weight; (2) types of carboxymethylcellulose have included high viscosity, medium viscosity, and low viscosity from 3 vendors (e.g., Aqualon® 7HF PH sodium carboxymethylcellulose from Hercules Incorporated, Hercules Plaza, 1313 North Market Street, Wilmington, Del. 19894-0001); (3) carboxymethylcellulose sterilized by gamma or electronic beam sterilization (medium and low doses); (4) demineralized bone matrix percentages up to 65% by volume; (5) differently processed demineralized bone matrix, air dried and freeze dried; (6) demineralized bone matrix from two vendors (e.g., human freeze dried demineralized bone matrix from AlloSource, 8085 E. Harvard Ave., Denver, Col. 80231); and (7) animal demineralized bone matrix, including bovine and canine.
- For all these formulations, varying amounts of water, between 31-200 parts by weight, have been tested. The mixing, handling, consistency, and injectability properties were assessed and formulas chosen such that they met the mixing, handability, ejectability, and robustness characteristics/criteria stated hereinabove.
- Paste And Putty Bone Graft Substitute Composition: These were the first tests done and included formulations with compositions having 100 parts by weight medical grade calcium sulfate hemihydrate, and between 1-10% by weight carboxymethylcellulose, and between 31-200 parts by weight water. As was the case with the injectable bone graft substitute composition, mixing, handability, consistency, injectability, and robustness properties were assessed for the different formulations. Specific tests have included: (1) varying the carboxymethylcellulose percentages from 0.25% up to 10% by weight, (2) using inorganic salt solutions including 2% sodium chloride (NaCl) by weight, 2-4% sodium sulfate (Na 2SO4) by weight, and 2% potassium chloride (KCl)by weight.
- As with the injectable bone graft substitute composition, varying amounts of water, 31-200 parts by weight, were used.
- The osteoinductive properties of the injectable bone graft substitute composition have been studied using an athymic mouse-intramuscular implantation model. This animal model is widely accepted as the “gold standard” for assessing osteoinductive characteristics of bone graft materials. In this model, a given amount of material is surgically placed into a muscular site. After an implantation period of four weeks, the osteoinductive response is assessed using various analytical methods, including radiography, biochemical analysis (alkaline phosphatase levels and calcium content), and histomorphometry.
- In this study, four athymic (nude) male mice (Harlan Sprague Dawley, Inc.) were used for each material group. Two muscle pouches were formed in the right and left gluteal muscles of each mouse and implanted with either: (1) pellets which were manufactured using the composition given in Preferred Embodiment 1, or (2) twenty (20) 5 mg of demineralized bone matrix which had been rehydrated with isotonic saline (0.9% NaCl). The pellets made from Preferred Embodiment 1 were 3.0 mm in diameter, 2.5 mm in height and 25 mg in weight.
- After twenty-eight (28) days the animals were sacrificed and the materials explanted. The explants were analyzed for osteoinductive potential by assessing the alkaline phosphatase activity and for new bone growth by histomorphometric analysis of histologic sections.
- Samples to be analyzed for alkaline phosphatase activity were minced, sonicated, and extracted with water saturated butanol. The extracts were assayed for protein content using a Pierce BCA Protein Assay Kit (Pierce Chemical Co.) and measuring the conversion of para-nitrophenylphosphate (pNPP)to para-nitrophenol (pNP) with time. The results were expressed as mole pNP formed/min/ g tissue protein.
- Samples intended for histomorphometric analyses were prepared using standard histological procedures. The percent viable bone (new bone formation) was quantitated employing computer software (Adobe Photo Shop 3.0.4 and HNIH 1.61), in conjunction with a microscope equipped with a video camera. Data was reported as percent viable bone relative to the total cross-sectional area analyzed.
- The alkaline phosphatase levels (μmole pNP formed/min/μg tissue protein) and percent viable bone results for the groups of mice implanted with DBM only and with injectable putty manufactured using the composition given in Preferred Embodiment 1 are shown in Table 1.
TABLE 1 Osteoinductive Results Alkaline Phosphatase Levels and Percent Viable Bone Alkaline Phosphatase Levels (μmole pNP formed/min/μg Percent Viable Bone Group tissue protein) (%) DMB only 2.1 × 10−5 ± 0.3 × 10−5 6.5% ± 1.0% Injectable Putty 3.0 × 10−5 ± 0.2 × 10−5 4.7% ± 0.9% (Preferred Embodiment 1) - A study was performed on canines to evaluate healing of bone defects using materials with the composition given in Preferred Embodiment 1. The DBM used in these compositions was fresh frozen canine DBM (Veterinarian Transplant Services, Seattle, Wash.). Two methods were used to produce the test materials. The first material group consisted of a blend of DBM, calcium sulfate, and CMC powder that was irradiated sterilized, while the second group mixed canine DBM with the calcium sulfate-CMC blend at the time of surgery.
- In this canine animal model, large medullary cylindrical defects (13 mm diameter ×50 mm length)were created bilaterally in the proximal humeri by drilling axially through the greater tubercle. Six to 7 cc of test material were injected into prepared cavities using a large-bore catheter-tip syringe. Left humeri received the premixed material that hand been sterilized and the right humeri received the material mixed intraoperatively which utilized non-irradiated canine DBM. Radiographs of the humeri were obtained preoperative, immediately postoperative, and at 2, 3, and 6 weeks. Following euthanasia after 6 weeks, the explanted humeri were sectioned transversely, radiographed, and processed for plastic imbedded undecalcified histology. The histologic sections were stained with basic fuchsin and toluidine blue and examined by light microscopy.
- Post-operative radiographs revealed all test materials to be well contained in the prepared cavities. Normal would healing occurred and there were no postoperative infections. Serial clinical radiographs showed a progressive decrease in materials density with time. No difference was evident between the right and left sides.
- Contact radiographs of the cut sections demonstrated no difference in pattern or density of bone filling the right and left defects, non-irradiated and irradiated canine DBM materials groups, respectively. Serial sections for all the dogs showed between 30-100% filling of the defect, with one dog showing almost complete filling for all sections.
- Histologically, the nature of new bone formation and the amount of residual material were similar in the right and left defects. In the peripheral one-third of the defects, new bone was present at the margins and haversian surfaces of abundant DBM particles. Residual calcium sulfate was evident, incorporated within slender bone trabeculae, independent of DBM particles. New bone formation in the central aspect of the defects was more variable, with some vascular fibrosus tissue shown. No foreign body or inflammatory response was seen in any of the slides, indicating that the materials had extremely good biocompatibilty.
- Thus, materials with compositions given in Preferred Embodiment 1 were shown to be well tolerated by the bone and to heal a large medullary defect 30-100% at six 20 weeks with viable new bone in a canine bone defect model.
- Although the present invention has been described and illustrated with respect to preferred embodiments and preferred uses therefor, it is not to be so limited since modifications and changes can be made therein which are within the full intended scope of the invention.
Claims (30)
1. A bone graft substitute composition, consisting essentially of:
calcium sulfate;
a mixing solution; and
a plasticizing substance.
2. The composition of claim 1 , wherein the calcium sulfate comprises calcium sulfate hemihydrate.
3. The composition of claim 1 , wherein the plasticizing substance comprises a cellulose derivative.
4. The composition of claim 1 , wherein the plasticizing substance is selected from a group consisting of sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, ethylcellulose, hydroxyethylcellulose, and cellulose acetate butyrate.
5. The composition of claim 1 , wherein the plasticizing substance comprises hydroxypropyl methyl cellulose.
6. The composition of claim 1 , wherein the plasticizing substance comprises hydroxypropyl cellulose.
7. The composition of claim 1 , wherein the plasticizing substance comprises hyaluronic acid.
8. The composition of claim 1 , wherein the plasticizing substance comprises methylcellulose.
9. The composition of claim 1 , wherein the mixing solution is selected from a group consisting of sterile water, inorganic salt, and cationic surface active agent.
10. The composition of claim 9 , wherein the cationic surface active agent is selected from a group consisting of sodium chloride, phosphate buffered saline, potassium chloride, sodium sulfate, ammonium sulfate, ammonium acetate, and sodium acetate.
11. The composition of claim 1 , wherein the mixing solution comprises sterile water.
12. The composition of claim 1 , wherein the composition does not comprise a polymer matrix.
13. The composition of claim 1 , wherein the composition does not comprise bone.
14. The composition of claim 1 , consisting essentially of:
100 parts by weight of the calcium sulfate;
about 1.5 to about 8 parts by weight of the plasticizing substance; and
about 25 to about 65 parts by weight of the mixing solution.
15. The composition of claim 1 , consisting essentially of:
100 parts of the calcium sulfate;
about 5.25 parts by weight of the plasticizing substance; and
about 33.6 parts by weight of the mixing solution.
16. A bone graft substitute composition, comprising:
calcium sulfate;
demineralized bone matrix;
cancellous bone;
a plasticizing substance; and
a mixing solution.
17. The composition of claim 16 , wherein the calcium sulfate comprises calcium sulfate hemihydrate.
18. The composition of claim 16 , wherein the plasticizing substance comprises a cellulose derivative.
19. The composition of claim 16 , wherein the plasticizing substance is selected from a group consisting of sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, ethylcellulose, hydroxyethylcellulose, and cellulose acetate butyrate.
20. The composition of claim 16 , wherein the mixing solution is selected from a group consisting of sterile water, inorganic salt, and cationic surface active agent.
21. The composition of claim 20 , wherein the cationic surface active agent is selected from a group consisting of sodium chloride, phosphate buffered saline, potassium chloride, sodium sulfate, ammonium sulfate, ammonium acetate, and sodium acetate.
22. The composition of claim 16 , wherein the mixing solution comprises sterile water.
23. The composition of claim 16 , comprising:
about 80 to about 120 parts by weight of calcium sulfate;
about 10 to about 100 parts by weight of demineralized bone matrix;
about 10 to about 100 parts by weight of cancellous bone;
about 1 to about 40 parts by weight of a plasticizing substance; and
about 21 to about 250 parts by weight of a mixing solution.
24. The composition of claim 16 , comprising:
about 90 to about 110 parts by weight of calcium sulfate;
about 10 to about 50 parts by weight of demineralized bone matrix;
about 15 to about 50 parts by weight of cancellous bone;
about 5 to about 20 parts by weight of a plasticizing substance; and
about 80 to about 120 parts by weight of a mixing solution.
25. The composition of claim 16 , comprising:
about 98 to about 102 parts by weight of calcium sulfate;
about 13 to about 23 parts by weight of demineralized bone matrix;
about 27 to about 33 parts by weight of cancellous bone;
about 15 to about 20 parts by weight of a plasticizing substance; and
about 95 to about 105 parts by weight of a mixing solution.
26. The composition of claim 16 , comprising:
about 100 parts by weight of calcium sulfate;
about 18 to about 19 parts by weight of demineralized bone matrix;
about 27 to about 28 parts by weight of cancellous bone;
about 17 to about 18 parts by weight of a plasticizing substance; and
about 101 to about 102 parts by weight of a mixing solution.
27. A bone graft substitute composition, comprising:
about 80 to about 120 parts by weight of calcium sulfate hemihydrate;
about 10 to about 100 parts by weight of demineralized bone matrix;
about 10 to about 100 parts by weight of cancellous bone;
about 1 to about 40 parts by weight of a carboxymethylcellulose; and
about 21 to about 250 parts by weight of sterile water.
28. The composition of claim 27 , comprising:
about 90 to about 110 parts by weight of calcium sulfate hemihydrate;
about 10 to about 50 parts by weight of demineralized bone matrix;
about 15 to about 50 parts by weight of cancellous bone;
about 5 to about 20 parts by weight of carboxymethylcellulose; and
about 80 to about 120 parts by weight of sterile water.
29. The composition of claim 27 , comprising:
about 98 to about 102 parts by weight of calcium sulfate hydrate;
about 13 to about 23 parts by weight of demineralized bone matrix;
about 27 to about 33 parts by weight of cancellous bone;
about 15 to about 20 parts by weight of carboxymethylcellulose; and
about 95 to about 105 parts by weight of sterile water.
30. The composition of claim 27 , comprising:
about 100 parts by weight of calcium sulfate hemihydrate;
about 18 to about 19 parts by weight of demineralized bone matrix;
about 27 to about 28 parts by weight of cancellous bone;
about 17 to about 18 parts by weight of carboxymethylcellulose; and
about 101 to about 102 parts by weight of sterile water.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/915,997 US20020071827A1 (en) | 1999-06-07 | 2001-07-26 | Bone graft substitute composition |
| US10/060,697 US7371410B2 (en) | 1999-06-07 | 2002-01-30 | Bone graft substitute composition |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/327,761 US7371408B1 (en) | 1999-06-07 | 1999-06-07 | Bone graft substitute composition |
| US09/915,997 US20020071827A1 (en) | 1999-06-07 | 2001-07-26 | Bone graft substitute composition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/327,761 Continuation-In-Part US7371408B1 (en) | 1999-06-07 | 1999-06-07 | Bone graft substitute composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/060,697 Continuation US7371410B2 (en) | 1999-06-07 | 2002-01-30 | Bone graft substitute composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20020071827A1 true US20020071827A1 (en) | 2002-06-13 |
Family
ID=23277952
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/327,761 Expired - Fee Related US7371408B1 (en) | 1999-06-07 | 1999-06-07 | Bone graft substitute composition |
| US09/915,997 Abandoned US20020071827A1 (en) | 1999-06-07 | 2001-07-26 | Bone graft substitute composition |
| US10/060,697 Expired - Lifetime US7371410B2 (en) | 1999-06-07 | 2002-01-30 | Bone graft substitute composition |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/327,761 Expired - Fee Related US7371408B1 (en) | 1999-06-07 | 1999-06-07 | Bone graft substitute composition |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/060,697 Expired - Lifetime US7371410B2 (en) | 1999-06-07 | 2002-01-30 | Bone graft substitute composition |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7371408B1 (en) |
| EP (1) | EP1198236B1 (en) |
| AU (1) | AU780355B2 (en) |
| CA (1) | CA2371612C (en) |
| DE (1) | DE60039515D1 (en) |
| WO (1) | WO2000074690A1 (en) |
Cited By (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030235621A1 (en) * | 2002-06-24 | 2003-12-25 | Miller Leasa C. | Bone graft substitute composition |
| WO2004000276A1 (en) * | 2002-06-20 | 2003-12-31 | Royer Biomedical, Inc. | Resorbable matrices with coatings for delivery of bioactive compounds |
| US20040062816A1 (en) * | 2002-07-31 | 2004-04-01 | Atkinson Brent L. | Bone repair putty |
| US20050020506A1 (en) * | 2003-07-25 | 2005-01-27 | Drapeau Susan J. | Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use |
| US20060165799A1 (en) * | 2002-09-30 | 2006-07-27 | In-San Kim | Bone-filling composition for stimulating bone-forming and bone-consolidation comprising calcium sulfate and viscous biopolymers |
| US20060233851A1 (en) * | 2005-04-13 | 2006-10-19 | Ebi, L.P. | Composite bone graft material |
| US20060233849A1 (en) * | 2005-04-13 | 2006-10-19 | Simon Bruce J | Composite bone graft material |
| US20070129809A1 (en) * | 2005-12-05 | 2007-06-07 | Biomet Manufacturing Corp. | Apparatus for use of porous implants |
| US20070186819A1 (en) * | 2002-03-29 | 2007-08-16 | Wright Medical Technology, Inc. | Bone Graft Substitute Composition |
| US20070250175A1 (en) * | 2001-02-23 | 2007-10-25 | Biomet Manufacturing Corp. | Method And Appartus For Acetabular Reconstruction |
| US20070254041A1 (en) * | 2006-05-01 | 2007-11-01 | Drapeau Susan J | Demineralized bone matrix devices |
| US20070254042A1 (en) * | 2006-05-01 | 2007-11-01 | Drapeau Susan J | Malleable implants containing demineralized bone matrix |
| WO2007070681A3 (en) * | 2005-12-16 | 2008-12-24 | Cerapedics Inc | Pliable medical device and method of use |
| US20090142385A1 (en) * | 2007-12-04 | 2009-06-04 | Warsaw Orthopedic, Inc. | Compositions for treating bone defects |
| US20090246244A1 (en) * | 2008-03-27 | 2009-10-01 | Warsaw Orthopedic, Inc. | Malleable multi-component implants and materials therefor |
| US7758621B2 (en) | 1997-05-15 | 2010-07-20 | Palomar Medical Technologies, Inc. | Method and apparatus for therapeutic EMR treatment on the skin |
| US7763016B2 (en) | 1997-05-15 | 2010-07-27 | Palomar Medical Technologies, Inc. | Light energy delivery head |
| US20100209470A1 (en) * | 2006-05-01 | 2010-08-19 | Warsaw Orthopedic, Inc. An Indiana Corporation | Demineralized bone matrix devices |
| US20100255115A1 (en) * | 2006-05-01 | 2010-10-07 | Warsaw Orthopedic, Inc. | Bone filler material |
| US7942915B2 (en) | 2002-05-23 | 2011-05-17 | Palomar Medical Technologies, Inc. | Phototreatment device for use with coolants |
| US8066778B2 (en) | 2005-04-21 | 2011-11-29 | Biomet Manufacturing Corp. | Porous metal cup with cobalt bearing surface |
| US8182473B2 (en) | 1999-01-08 | 2012-05-22 | Palomar Medical Technologies | Cooling system for a photocosmetic device |
| US8266780B2 (en) | 2005-04-21 | 2012-09-18 | Biomet Manufacturing Corp. | Method and apparatus for use of porous implants |
| US8292967B2 (en) * | 2005-04-21 | 2012-10-23 | Biomet Manufacturing Corp. | Method and apparatus for use of porous implants |
| CN101507840B (en) * | 2009-03-25 | 2012-11-14 | 上海市肿瘤研究所 | Liposome calcium sulphate composite nano artificial bone, preparation method and use thereof |
| US8328794B2 (en) | 1996-12-02 | 2012-12-11 | Palomar Medical Technologies, Inc. | System for electromagnetic radiation dermatology and head for use therewith |
| US8346347B2 (en) | 2005-09-15 | 2013-01-01 | Palomar Medical Technologies, Inc. | Skin optical characterization device |
| US8876532B2 (en) | 2002-07-31 | 2014-11-04 | Dentsply International Inc. | Bone repair putty |
| US8915948B2 (en) | 2002-06-19 | 2014-12-23 | Palomar Medical Technologies, Llc | Method and apparatus for photothermal treatment of tissue at depth |
| US9028536B2 (en) | 2006-08-02 | 2015-05-12 | Cynosure, Inc. | Picosecond laser apparatus and methods for its operation and use |
| US9780518B2 (en) | 2012-04-18 | 2017-10-03 | Cynosure, Inc. | Picosecond laser apparatus and methods for treating target tissues with same |
| US9919168B2 (en) | 2009-07-23 | 2018-03-20 | Palomar Medical Technologies, Inc. | Method for improvement of cellulite appearance |
| US10245107B2 (en) | 2013-03-15 | 2019-04-02 | Cynosure, Inc. | Picosecond optical radiation systems and methods of use |
| US10434324B2 (en) | 2005-04-22 | 2019-10-08 | Cynosure, Llc | Methods and systems for laser treatment using non-uniform output beam |
| US11235086B2 (en) | 2018-02-22 | 2022-02-01 | Cerapedics, Inc. | Processes for coating inorganic particles with a peptide or protein useful for improving cellular activity related to bone growth |
| CN114438597A (en) * | 2021-12-31 | 2022-05-06 | 佛山市中医院 | Tissue engineering polyester composite scaffold material with calcium sulfate enhanced in-situ solidification pore-forming function and preparation method and application thereof |
| US11418000B2 (en) | 2018-02-26 | 2022-08-16 | Cynosure, Llc | Q-switched cavity dumped sub-nanosecond laser |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7019192B2 (en) * | 1998-02-27 | 2006-03-28 | Musculoskeletal Transplant Foundation | Composition for filling bone defects |
| WO2001066044A2 (en) * | 2000-03-03 | 2001-09-13 | Smith & Nephew, Inc. | Shaped particle and composition for bone deficiency and method of making the particle |
| US7575780B2 (en) * | 2000-08-07 | 2009-08-18 | Orthogen Llc | Method for manufacturing particles for use in forming a resorbable implant for stimulating bone growth |
| US6770695B2 (en) * | 2000-08-07 | 2004-08-03 | John L. Ricci | Time release calcium sulfate matrix for bone augmentation |
| US20020114795A1 (en) | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
| KR100435419B1 (en) * | 2001-03-30 | 2004-06-10 | 주식회사 리젠 바이오텍 | Bone-filling composition for stimulating bone-forming and bone-consolidation comprising calcium sulfate and viscous biopolymers |
| EP1364662A1 (en) * | 2002-05-15 | 2003-11-26 | Central Medical Technologies Inc. | Gypsum composition for use in bone restoration operation with controlled working time |
| US7507257B2 (en) * | 2003-02-04 | 2009-03-24 | Wright Medical Technology, Inc. | Injectable resorbable bone graft material, powder for forming same and methods relating thereto for treating bone defects |
| US7250550B2 (en) | 2004-10-22 | 2007-07-31 | Wright Medical Technology, Inc. | Synthetic bone substitute material |
| FR2876917B1 (en) * | 2004-10-22 | 2007-03-09 | Tbf Banque De Tissus | BONE FILLING COMPOSITION |
| DE102004060666B3 (en) | 2004-12-15 | 2006-03-30 | Heraeus Kulzer Gmbh | Antibiotic-containing bone substitute material comprises a compacted mixture of antibiotic-containing mineral granules and a binder |
| US8137664B2 (en) * | 2005-02-02 | 2012-03-20 | Sdgi Holdings, Inc. | Method and kit for repairing a defect in bone |
| US8025903B2 (en) | 2005-09-09 | 2011-09-27 | Wright Medical Technology, Inc. | Composite bone graft substitute cement and articles produced therefrom |
| CN103349793B (en) | 2005-09-09 | 2016-02-10 | 阿格诺沃斯健康关爱公司 | Composite bone graft substitute cement and the goods obtained by it |
| WO2007068489A2 (en) * | 2005-12-14 | 2007-06-21 | Scil Technology Gmbh | A moldable biomaterial for bone regeneration |
| US8690957B2 (en) | 2005-12-21 | 2014-04-08 | Warsaw Orthopedic, Inc. | Bone graft composition, method and implant |
| CA2616421A1 (en) * | 2006-05-23 | 2007-11-29 | Mathys Ag Bettlach | Solid precursor for the preparation of a pasty bone replacement material by admixture of a liquid. |
| WO2007146946A2 (en) * | 2006-06-13 | 2007-12-21 | Xylos Corporation | Implantable microbial cellulose materials for hard tissue repair and regeneration |
| WO2008066382A1 (en) * | 2006-11-29 | 2008-06-05 | Cam Aesthetics B.V. I.O. | Carboxymethyl cellulose-stabilised tissue filler and its preparation and use |
| KR100846836B1 (en) * | 2007-01-15 | 2008-07-17 | 한스바이오메드 주식회사 | Composition for promoting bone regeneration and restoration |
| US8431148B2 (en) * | 2007-03-08 | 2013-04-30 | Warsaw Orthopedic, Inc. | Bone void filler |
| TWI579007B (en) | 2010-07-02 | 2017-04-21 | 艾格諾福斯保健公司 | Use of bone regenerative material |
| DE102010055561B4 (en) | 2010-12-23 | 2015-12-31 | Heraeus Medical Gmbh | Coating method and coating device |
| US9358122B2 (en) | 2011-01-07 | 2016-06-07 | K2M, Inc. | Interbody spacer |
| WO2015036992A2 (en) | 2013-09-10 | 2015-03-19 | Augma Biomaterials Ltd. | Dual component applicator |
| TWI651103B (en) | 2013-12-13 | 2019-02-21 | 萊特醫技股份有限公司 | Multiphase bone graft replacement material |
| TW201801709A (en) * | 2016-07-12 | 2018-01-16 | 三鼎生物科技股份有限公司 | Bone repairing material and method for producing thereof |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4568536A (en) * | 1985-02-08 | 1986-02-04 | Ethicon, Inc. | Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition |
| US4595713A (en) * | 1985-01-22 | 1986-06-17 | Hexcel Corporation | Medical putty for tissue augmentation |
| US4612009A (en) * | 1984-06-19 | 1986-09-16 | Ceskoslovenska Akademie Ved | Biodegradable implant and a method for preparation thereof |
| US4650665A (en) * | 1985-02-08 | 1987-03-17 | Ethicon, Inc. | Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition |
| US4735802A (en) * | 1986-05-05 | 1988-04-05 | Le Bich N | Topical dermatological composition and method of treatment |
| US4820306A (en) * | 1981-06-22 | 1989-04-11 | Sterling Drug Inc. | Method for augmentation of the alveolar ridge |
| US4892734A (en) * | 1987-04-06 | 1990-01-09 | Endocon, Inc. | Dispensing paste for forming medicinal pellets |
| US5462722A (en) * | 1991-04-17 | 1995-10-31 | Liu; Sung-Tsuen | Calcium phosphate calcium sulfate composite implant material |
| US5578662A (en) * | 1994-07-22 | 1996-11-26 | United States Surgical Corporation | Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom |
| US5681873A (en) * | 1993-10-14 | 1997-10-28 | Atrix Laboratories, Inc. | Biodegradable polymeric composition |
| US5697981A (en) * | 1994-08-23 | 1997-12-16 | Norian Corporation | Method for repairing bone |
| US5727945A (en) * | 1996-08-26 | 1998-03-17 | Dannenbaum; Richard M. | Impregnated barrier and method of assisting bone or tissue regeneration |
| US5824087A (en) * | 1994-04-11 | 1998-10-20 | Aberdeen University And Plasma Biotal Limited | Bone regeneration |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB999487A (en) * | 1963-05-03 | 1965-07-28 | Ici Ltd | Set-retarded calcium sulphate hemihydrate |
| US4430760A (en) | 1981-12-18 | 1984-02-14 | Collagen Corporation | Nonstress-bearing implantable bone prosthesis |
| GB2093348B (en) | 1981-02-23 | 1984-09-12 | Leo Pharm Prod Ltd | Pharmaceutical composition for implantation |
| US4619655A (en) * | 1984-01-26 | 1986-10-28 | University Of North Carolina | Plaster of Paris as a bioresorbable scaffold in implants for bone repair |
| US4596574A (en) | 1984-05-14 | 1986-06-24 | The Regents Of The University Of California | Biodegradable porous ceramic delivery system for bone morphogenetic protein |
| GB8514055D0 (en) | 1985-06-04 | 1985-07-10 | Geistlich Soehne Ag | Chemical substance |
| US4681763A (en) | 1985-06-11 | 1987-07-21 | University Of Medicine And Dentistry Of New Jersey | Composition for stimulating bone growth |
| US4880660A (en) | 1987-08-28 | 1989-11-14 | Minnesota Mining And Manufacturing Company | Method for priming hard tissue |
| CA1339083C (en) | 1987-11-13 | 1997-07-29 | Steven R. Jefferies | Bone repair material and delayed drug delivery system |
| US5162114A (en) | 1989-02-23 | 1992-11-10 | Stryker Corporation | Bone collagen matrix for xenogenic implants |
| US4975526A (en) | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
| GB8813033D0 (en) | 1988-06-02 | 1988-07-06 | Geistlich Soehne Ag | Chemical compound |
| US4994030A (en) | 1988-06-28 | 1991-02-19 | Osteotech, Inc. | Reconstitution of human bone and tissue |
| US5573771A (en) | 1988-08-19 | 1996-11-12 | Osteomedical Limited | Medicinal bone mineral products |
| US5264214A (en) | 1988-11-21 | 1993-11-23 | Collagen Corporation | Composition for bone repair |
| US5147403A (en) | 1989-03-15 | 1992-09-15 | United States Gypsum Company | Prosthesis implantation method |
| US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
| US5061286A (en) | 1989-08-18 | 1991-10-29 | Osteotech, Inc. | Osteoprosthetic implant |
| US5073373A (en) | 1989-09-21 | 1991-12-17 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
| US5290558A (en) | 1989-09-21 | 1994-03-01 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
| US5236456A (en) | 1989-11-09 | 1993-08-17 | Osteotech, Inc. | Osteogenic composition and implant containing same |
| US5425769A (en) * | 1990-04-23 | 1995-06-20 | Snyders, Jr.; Robert V. | Composition of material for osseous repair |
| EP0483944B1 (en) | 1990-10-31 | 1995-07-05 | El Gendler | Flexible membranes produced from organic bone matrix for skeletal repair and reconstruction |
| DE4121043A1 (en) | 1991-06-26 | 1993-01-07 | Merck Patent Gmbh | BONE REPLACEMENT MATERIAL WITH FGF |
| US5769897A (en) | 1991-12-13 | 1998-06-23 | Haerle; Anton | Synthetic bone |
| US5314476A (en) | 1992-02-04 | 1994-05-24 | Osteotech, Inc. | Demineralized bone particles and flowable osteogenic composition containing same |
| US5236971A (en) | 1992-02-10 | 1993-08-17 | Murray William M | Dental and orthopedic cement method and preforms |
| US5219897A (en) | 1992-02-10 | 1993-06-15 | Murray William M | Dental and orthopedic cement method and preforms |
| US5336699A (en) | 1992-02-20 | 1994-08-09 | Orthopaedic Research Institute | Bone cement having chemically joined reinforcing fillers |
| US5366507A (en) | 1992-03-06 | 1994-11-22 | Sottosanti John S | Method for use in bone tissue regeneration |
| US5320844A (en) | 1992-03-12 | 1994-06-14 | Liu Sung Tsuen | Composite materials for hard tissue replacement |
| US5334626A (en) | 1992-07-28 | 1994-08-02 | Zimmer, Inc. | Bone cement composition and method of manufacture |
| FR2705235B1 (en) | 1993-05-13 | 1995-07-13 | Inoteb | Use of particles of a biocompatible and bioresorbable calcium salt as an active ingredient in the preparation of a medicament for the local treatment of demineralizing bone diseases. |
| US5531791A (en) | 1993-07-23 | 1996-07-02 | Bioscience Consultants | Composition for repair of defects in osseous tissues, method of making, and prosthesis |
| US5385887A (en) | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| US5482551A (en) | 1993-09-20 | 1996-01-09 | Armstrong World Industries, Inc. | Extruded fire resistant construction and building products |
| US5507813A (en) | 1993-12-09 | 1996-04-16 | Osteotech, Inc. | Shaped materials derived from elongate bone particles |
| US5763416A (en) | 1994-02-18 | 1998-06-09 | The Regent Of The University Of Michigan | Gene transfer into bone cells and tissues |
| US5626861A (en) | 1994-04-01 | 1997-05-06 | Massachusetts Institute Of Technology | Polymeric-hydroxyapatite bone composite |
| US5707962A (en) | 1994-09-28 | 1998-01-13 | Gensci Regeneration Sciences Inc. | Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof |
| TW369414B (en) | 1994-09-30 | 1999-09-11 | Yamanouchi Pharma Co Ltd | Bone formation transplant |
| US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
| EP0851772A1 (en) | 1995-06-06 | 1998-07-08 | Gensci Regeneration Laboratories, Inc. | Modified osteogenic materials |
| US5700289A (en) | 1995-10-20 | 1997-12-23 | North Shore University Hospital Research Corporation | Tissue-engineered bone repair using cultured periosteal cells |
| US6048964A (en) | 1995-12-12 | 2000-04-11 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
| US5788976A (en) | 1996-02-12 | 1998-08-04 | Wbk, Inc. | Method for effecting bone repair |
| US5824078A (en) | 1996-03-11 | 1998-10-20 | The Board Of Trustees Of The University Of Arkansas | Composite allograft, press, and methods |
| DE19620117C1 (en) | 1996-05-18 | 1997-07-24 | Corimed Kundenorientierte Medi | Preparation of medicinal composition containing calcium sulphate |
| US6051247A (en) | 1996-05-30 | 2000-04-18 | University Of Florida Research Foundation, Inc. | Moldable bioactive compositions |
| US5964805A (en) | 1997-02-12 | 1999-10-12 | Stone; Kevin R. | Method and paste for articular cartilage transplantation |
| US5676146B1 (en) | 1996-09-13 | 2000-04-18 | Osteotech Inc | Surgical implant containing a resorbable radiopaque marker and method of locating such within a body |
| US6037519A (en) | 1997-10-20 | 2000-03-14 | Sdgi Holdings, Inc. | Ceramic fusion implants and compositions |
| US5756127A (en) * | 1996-10-29 | 1998-05-26 | Wright Medical Technology, Inc. | Implantable bioresorbable string of calcium sulfate beads |
| AU6019898A (en) | 1997-01-09 | 1998-08-03 | Cohesion Technologies, Inc. | Devices for tissue repair and methods for preparation and use thereof |
| US20020098222A1 (en) | 1997-03-13 | 2002-07-25 | John F. Wironen | Bone paste |
| US5948426A (en) | 1997-05-03 | 1999-09-07 | Jefferies; Steven R. | Method and article to induce hematopoietic expansion |
| US5861445A (en) | 1997-05-08 | 1999-01-19 | American Dental Association Health Foundation | Reinforcement of dental and other composite materials |
| US5972368A (en) | 1997-06-11 | 1999-10-26 | Sdgi Holdings, Inc. | Bone graft composites and spacers |
| US5910315A (en) | 1997-07-18 | 1999-06-08 | Stevenson; Sharon | Allograft tissue material for filling spinal fusion cages or related surgical spaces |
| US6391336B1 (en) | 1997-09-22 | 2002-05-21 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
| US5899939A (en) | 1998-01-21 | 1999-05-04 | Osteotech, Inc. | Bone-derived implant for load-supporting applications |
| US6030635A (en) * | 1998-02-27 | 2000-02-29 | Musculoskeletal Transplant Foundation | Malleable paste for filling bone defects |
| US6056970A (en) | 1998-05-07 | 2000-05-02 | Genzyme Corporation | Compositions comprising hemostatic compounds and bioabsorbable polymers |
| US6224635B1 (en) * | 1998-11-06 | 2001-05-01 | Hospital For Joint Diseases | Implantation of surgical implants with calcium sulfate |
| EP1301222B1 (en) | 2000-07-19 | 2005-12-14 | Osteotech, Inc. | Osteoimplant and method of making same |
| US6770695B2 (en) * | 2000-08-07 | 2004-08-03 | John L. Ricci | Time release calcium sulfate matrix for bone augmentation |
-
1999
- 1999-06-07 US US09/327,761 patent/US7371408B1/en not_active Expired - Fee Related
-
2000
- 2000-02-02 DE DE60039515T patent/DE60039515D1/en not_active Expired - Lifetime
- 2000-02-02 CA CA002371612A patent/CA2371612C/en not_active Expired - Lifetime
- 2000-02-02 EP EP00914492A patent/EP1198236B1/en not_active Expired - Lifetime
- 2000-02-02 AU AU35876/00A patent/AU780355B2/en not_active Expired
- 2000-02-02 WO PCT/US2000/002780 patent/WO2000074690A1/en active IP Right Grant
-
2001
- 2001-07-26 US US09/915,997 patent/US20020071827A1/en not_active Abandoned
-
2002
- 2002-01-30 US US10/060,697 patent/US7371410B2/en not_active Expired - Lifetime
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4820306A (en) * | 1981-06-22 | 1989-04-11 | Sterling Drug Inc. | Method for augmentation of the alveolar ridge |
| US4612009A (en) * | 1984-06-19 | 1986-09-16 | Ceskoslovenska Akademie Ved | Biodegradable implant and a method for preparation thereof |
| US4595713A (en) * | 1985-01-22 | 1986-06-17 | Hexcel Corporation | Medical putty for tissue augmentation |
| US4568536A (en) * | 1985-02-08 | 1986-02-04 | Ethicon, Inc. | Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition |
| US4650665A (en) * | 1985-02-08 | 1987-03-17 | Ethicon, Inc. | Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition |
| US4735802A (en) * | 1986-05-05 | 1988-04-05 | Le Bich N | Topical dermatological composition and method of treatment |
| US4892734A (en) * | 1987-04-06 | 1990-01-09 | Endocon, Inc. | Dispensing paste for forming medicinal pellets |
| US5462722A (en) * | 1991-04-17 | 1995-10-31 | Liu; Sung-Tsuen | Calcium phosphate calcium sulfate composite implant material |
| US5681873A (en) * | 1993-10-14 | 1997-10-28 | Atrix Laboratories, Inc. | Biodegradable polymeric composition |
| US5824087A (en) * | 1994-04-11 | 1998-10-20 | Aberdeen University And Plasma Biotal Limited | Bone regeneration |
| US5578662A (en) * | 1994-07-22 | 1996-11-26 | United States Surgical Corporation | Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom |
| US5697981A (en) * | 1994-08-23 | 1997-12-16 | Norian Corporation | Method for repairing bone |
| US5727945A (en) * | 1996-08-26 | 1998-03-17 | Dannenbaum; Richard M. | Impregnated barrier and method of assisting bone or tissue regeneration |
Cited By (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8328794B2 (en) | 1996-12-02 | 2012-12-11 | Palomar Medical Technologies, Inc. | System for electromagnetic radiation dermatology and head for use therewith |
| US8109924B2 (en) | 1997-05-15 | 2012-02-07 | Palomar Medical Technologies, Inc. | Heads for dermatology treatment |
| US7758621B2 (en) | 1997-05-15 | 2010-07-20 | Palomar Medical Technologies, Inc. | Method and apparatus for therapeutic EMR treatment on the skin |
| US8002768B1 (en) | 1997-05-15 | 2011-08-23 | Palomar Medical Technologies, Inc. | Light energy delivery head |
| US7763016B2 (en) | 1997-05-15 | 2010-07-27 | Palomar Medical Technologies, Inc. | Light energy delivery head |
| US7935107B2 (en) | 1997-05-15 | 2011-05-03 | Palomar Medical Technologies, Inc. | Heads for dermatology treatment |
| US8328796B2 (en) | 1997-05-15 | 2012-12-11 | Palomar Medical Technologies, Inc. | Light energy delivery head |
| US8182473B2 (en) | 1999-01-08 | 2012-05-22 | Palomar Medical Technologies | Cooling system for a photocosmetic device |
| US9375316B2 (en) | 2001-02-23 | 2016-06-28 | Biomet Manufacturing, Llc. | Method and apparatus for acetabular reconstruction |
| US20070250175A1 (en) * | 2001-02-23 | 2007-10-25 | Biomet Manufacturing Corp. | Method And Appartus For Acetabular Reconstruction |
| US8551181B2 (en) | 2001-02-23 | 2013-10-08 | Biomet Manufacturing, Llc | Method and apparatus for acetabular reconstruction |
| US8123814B2 (en) | 2001-02-23 | 2012-02-28 | Biomet Manufacturing Corp. | Method and appartus for acetabular reconstruction |
| US20070186819A1 (en) * | 2002-03-29 | 2007-08-16 | Wright Medical Technology, Inc. | Bone Graft Substitute Composition |
| US8657952B2 (en) | 2002-03-29 | 2014-02-25 | Wright Medical Technology, Inc. | Bone graft substitute composition |
| US8968465B2 (en) | 2002-03-29 | 2015-03-03 | Wright Medical Technology, Inc. | Bone graft substitute composition |
| US7942915B2 (en) | 2002-05-23 | 2011-05-17 | Palomar Medical Technologies, Inc. | Phototreatment device for use with coolants |
| US7942916B2 (en) | 2002-05-23 | 2011-05-17 | Palomar Medical Technologies, Inc. | Phototreatment device for use with coolants and topical substances |
| US10556123B2 (en) | 2002-06-19 | 2020-02-11 | Palomar Medical Technologies, Llc | Method and apparatus for treatment of cutaneous and subcutaneous conditions |
| US10500413B2 (en) | 2002-06-19 | 2019-12-10 | Palomar Medical Technologies, Llc | Method and apparatus for treatment of cutaneous and subcutaneous conditions |
| US8915948B2 (en) | 2002-06-19 | 2014-12-23 | Palomar Medical Technologies, Llc | Method and apparatus for photothermal treatment of tissue at depth |
| WO2004000276A1 (en) * | 2002-06-20 | 2003-12-31 | Royer Biomedical, Inc. | Resorbable matrices with coatings for delivery of bioactive compounds |
| US20050266077A1 (en) * | 2002-06-20 | 2005-12-01 | Royal Biomedical, Inc. | Resorbable matrices with coatings for delivery of bioactive compounds |
| US20030235621A1 (en) * | 2002-06-24 | 2003-12-25 | Miller Leasa C. | Bone graft substitute composition |
| US7291179B2 (en) * | 2002-06-24 | 2007-11-06 | Wright Medical Technology, Inc. | Bone graft substitute composition |
| US7658768B2 (en) | 2002-06-24 | 2010-02-09 | Wright Medical Technology, Inc. | Bone graft substitute composition |
| US8876532B2 (en) | 2002-07-31 | 2014-11-04 | Dentsply International Inc. | Bone repair putty |
| US7842300B2 (en) * | 2002-07-31 | 2010-11-30 | Dentsply International, Inc. | Bone repair putty |
| US20040062816A1 (en) * | 2002-07-31 | 2004-04-01 | Atkinson Brent L. | Bone repair putty |
| US7374776B2 (en) * | 2002-09-30 | 2008-05-20 | Regen Biotech, Inc. | Bone-filling composition for stimulating bone-forming and bone-consolidation comprising calcium sulfate and viscous biopolymers |
| US20060165799A1 (en) * | 2002-09-30 | 2006-07-27 | In-San Kim | Bone-filling composition for stimulating bone-forming and bone-consolidation comprising calcium sulfate and viscous biopolymers |
| US20050020506A1 (en) * | 2003-07-25 | 2005-01-27 | Drapeau Susan J. | Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use |
| US20060233849A1 (en) * | 2005-04-13 | 2006-10-19 | Simon Bruce J | Composite bone graft material |
| US20060233851A1 (en) * | 2005-04-13 | 2006-10-19 | Ebi, L.P. | Composite bone graft material |
| US7621963B2 (en) | 2005-04-13 | 2009-11-24 | Ebi, Llc | Composite bone graft material |
| US8266780B2 (en) | 2005-04-21 | 2012-09-18 | Biomet Manufacturing Corp. | Method and apparatus for use of porous implants |
| US8066778B2 (en) | 2005-04-21 | 2011-11-29 | Biomet Manufacturing Corp. | Porous metal cup with cobalt bearing surface |
| US8292967B2 (en) * | 2005-04-21 | 2012-10-23 | Biomet Manufacturing Corp. | Method and apparatus for use of porous implants |
| US10434324B2 (en) | 2005-04-22 | 2019-10-08 | Cynosure, Llc | Methods and systems for laser treatment using non-uniform output beam |
| US8346347B2 (en) | 2005-09-15 | 2013-01-01 | Palomar Medical Technologies, Inc. | Skin optical characterization device |
| US20070129809A1 (en) * | 2005-12-05 | 2007-06-07 | Biomet Manufacturing Corp. | Apparatus for use of porous implants |
| US8021432B2 (en) | 2005-12-05 | 2011-09-20 | Biomet Manufacturing Corp. | Apparatus for use of porous implants |
| US8048443B2 (en) | 2005-12-16 | 2011-11-01 | Cerapedics, Inc. | Pliable medical device and method of use |
| US9101694B2 (en) | 2005-12-16 | 2015-08-11 | Cerapedics Inc. | Pliable medical device and method of use |
| WO2007070681A3 (en) * | 2005-12-16 | 2008-12-24 | Cerapedics Inc | Pliable medical device and method of use |
| US20070254042A1 (en) * | 2006-05-01 | 2007-11-01 | Drapeau Susan J | Malleable implants containing demineralized bone matrix |
| US8039016B2 (en) | 2006-05-01 | 2011-10-18 | Warsaw Orthopedic, Inc. | Malleable implants containing demineralized bone matrix |
| US20100209470A1 (en) * | 2006-05-01 | 2010-08-19 | Warsaw Orthopedic, Inc. An Indiana Corporation | Demineralized bone matrix devices |
| US8431147B2 (en) | 2006-05-01 | 2013-04-30 | Warsaw Orthopedic, Inc. | Malleable implants containing demineralized bone matrix |
| US8506983B2 (en) | 2006-05-01 | 2013-08-13 | Warsaw Orthopedic, Inc. | Bone filler material |
| US7771741B2 (en) | 2006-05-01 | 2010-08-10 | Warsaw Orthopedic, Inc | Demineralized bone matrix devices |
| US7838022B2 (en) | 2006-05-01 | 2010-11-23 | Warsaw Orthopedic, Inc | Malleable implants containing demineralized bone matrix |
| US20100255115A1 (en) * | 2006-05-01 | 2010-10-07 | Warsaw Orthopedic, Inc. | Bone filler material |
| US9364582B2 (en) | 2006-05-01 | 2016-06-14 | Warsaw Orthopedic, Inc. | Malleable implants containing demineralized bone matrix |
| US20100209474A1 (en) * | 2006-05-01 | 2010-08-19 | Warsaw Orthopedic, Inc. | Malleable implants containing demineralized bone matrix |
| US20080152691A1 (en) * | 2006-05-01 | 2008-06-26 | Warsaw Orthopedic, Inc. | Malleable implants containing demineralized bone matrix |
| US8282953B2 (en) | 2006-05-01 | 2012-10-09 | Warsaw Orthopedic, Inc. | Malleable implants containing demineralized bone matrix |
| US20070254041A1 (en) * | 2006-05-01 | 2007-11-01 | Drapeau Susan J | Demineralized bone matrix devices |
| US9028536B2 (en) | 2006-08-02 | 2015-05-12 | Cynosure, Inc. | Picosecond laser apparatus and methods for its operation and use |
| US10849687B2 (en) | 2006-08-02 | 2020-12-01 | Cynosure, Llc | Picosecond laser apparatus and methods for its operation and use |
| US10966785B2 (en) | 2006-08-02 | 2021-04-06 | Cynosure, Llc | Picosecond laser apparatus and methods for its operation and use |
| US11712299B2 (en) | 2006-08-02 | 2023-08-01 | Cynosure, LLC. | Picosecond laser apparatus and methods for its operation and use |
| US10080819B2 (en) | 2007-12-04 | 2018-09-25 | Warsaw Orthopedic, Inc | Compositions for treating bone defects |
| US20090142385A1 (en) * | 2007-12-04 | 2009-06-04 | Warsaw Orthopedic, Inc. | Compositions for treating bone defects |
| US10441679B2 (en) | 2007-12-04 | 2019-10-15 | Warsaw Orthopedic, Inc. | Compositions for treating bone defects |
| US9056150B2 (en) | 2007-12-04 | 2015-06-16 | Warsaw Orthopedic, Inc. | Compositions for treating bone defects |
| US8840913B2 (en) | 2008-03-27 | 2014-09-23 | Warsaw Orthopedic, Inc. | Malleable multi-component implants and materials therefor |
| US20090246244A1 (en) * | 2008-03-27 | 2009-10-01 | Warsaw Orthopedic, Inc. | Malleable multi-component implants and materials therefor |
| US9730982B2 (en) | 2008-03-27 | 2017-08-15 | Warsaw Orthopedic, Inc. | Malleable multi-component implants and materials therefor |
| CN101507840B (en) * | 2009-03-25 | 2012-11-14 | 上海市肿瘤研究所 | Liposome calcium sulphate composite nano artificial bone, preparation method and use thereof |
| US9919168B2 (en) | 2009-07-23 | 2018-03-20 | Palomar Medical Technologies, Inc. | Method for improvement of cellulite appearance |
| US11664637B2 (en) | 2012-04-18 | 2023-05-30 | Cynosure, Llc | Picosecond laser apparatus and methods for treating target tissues with same |
| US10581217B2 (en) | 2012-04-18 | 2020-03-03 | Cynosure, Llc | Picosecond laser apparatus and methods for treating target tissues with same |
| US10305244B2 (en) | 2012-04-18 | 2019-05-28 | Cynosure, Llc | Picosecond laser apparatus and methods for treating target tissues with same |
| US11095087B2 (en) | 2012-04-18 | 2021-08-17 | Cynosure, Llc | Picosecond laser apparatus and methods for treating target tissues with same |
| US9780518B2 (en) | 2012-04-18 | 2017-10-03 | Cynosure, Inc. | Picosecond laser apparatus and methods for treating target tissues with same |
| US10765478B2 (en) | 2013-03-15 | 2020-09-08 | Cynosurce, Llc | Picosecond optical radiation systems and methods of use |
| US11446086B2 (en) | 2013-03-15 | 2022-09-20 | Cynosure, Llc | Picosecond optical radiation systems and methods of use |
| US10285757B2 (en) | 2013-03-15 | 2019-05-14 | Cynosure, Llc | Picosecond optical radiation systems and methods of use |
| US10245107B2 (en) | 2013-03-15 | 2019-04-02 | Cynosure, Inc. | Picosecond optical radiation systems and methods of use |
| US11235086B2 (en) | 2018-02-22 | 2022-02-01 | Cerapedics, Inc. | Processes for coating inorganic particles with a peptide or protein useful for improving cellular activity related to bone growth |
| US11418000B2 (en) | 2018-02-26 | 2022-08-16 | Cynosure, Llc | Q-switched cavity dumped sub-nanosecond laser |
| US11791603B2 (en) | 2018-02-26 | 2023-10-17 | Cynosure, LLC. | Q-switched cavity dumped sub-nanosecond laser |
| CN114438597A (en) * | 2021-12-31 | 2022-05-06 | 佛山市中医院 | Tissue engineering polyester composite scaffold material with calcium sulfate enhanced in-situ solidification pore-forming function and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US20020110541A1 (en) | 2002-08-15 |
| AU3587600A (en) | 2000-12-28 |
| AU780355B2 (en) | 2005-03-17 |
| US7371410B2 (en) | 2008-05-13 |
| EP1198236A4 (en) | 2004-04-07 |
| EP1198236B1 (en) | 2008-07-16 |
| CA2371612A1 (en) | 2000-12-14 |
| EP1198236A1 (en) | 2002-04-24 |
| US7371408B1 (en) | 2008-05-13 |
| WO2000074690A1 (en) | 2000-12-14 |
| DE60039515D1 (en) | 2008-08-28 |
| CA2371612C (en) | 2008-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7371410B2 (en) | Bone graft substitute composition | |
| US7371409B2 (en) | Bone graft substitute composition | |
| AU2010275697B2 (en) | Injectable and moldable osteoinductive ceramic materials | |
| US7658768B2 (en) | Bone graft substitute composition | |
| EP1477176B1 (en) | Malleable bone composition for filling bone defects | |
| Carey et al. | Premixed rapid-setting calcium phosphate composites for bone repair | |
| JP5795577B2 (en) | Solid form for tissue repair | |
| US20060204544A1 (en) | Allograft bone composition having a gelatin binder | |
| JP2012519556A (en) | Platelet-derived growth factor compositions and methods for treating osteochondral defects | |
| US7658940B2 (en) | Calcium phosphate cements comprising autologous bone | |
| JP2001509419A (en) | Moldable bioactive composition | |
| US20120021008A1 (en) | Injectable and moldable ceramic materials | |
| US20120088721A1 (en) | Cartilage Repair | |
| CN113749825A (en) | Frame type bone joint prosthesis and preparation method and application thereof | |
| CN102462863A (en) | Polyvinylpyrrolidone composite material used for bone defect restoration, its preparation method and its application method | |
| Clarke et al. | Testing bone substitutes in a small animal model of revision arthroplasty |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: WRIGHT MEDICAL TECHNOLOGY, INC., TENNESSEE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PETERSEN, DONALD W.;RICHELSOPH, KELLY COUPE;HAGGARD, WARREN OLIVER;AND OTHERS;REEL/FRAME:012446/0160;SIGNING DATES FROM 20011011 TO 20011115 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |